InvestorsHub Logo

DewDiligence

10/19/17 4:43 PM

#2679 RE: shub #2678

FDA approval of Yescarta was a fait accompli, and the list price turned out to be in line with expectations. So, all told, the stock's being +2% today is a pretty good move.